Amylyx appoints Dr. Bernhardt Zeiher to board, fills Class I director vacancy

Amylyx Pharmaceuticals, Inc.

Appointed March 14, 2024 as Class I director; term expires at 2025 annual meeting.
Also named to Nominating and Corporate Governance Committee, replacing Paul Fonteyne.
Zeiher was Chief Medical Officer at Astellas Pharma from 2018-2022; joined Entrada Therapeutics board in 2023.
Receives initial option grant (lesser of $570K value or 50K shares); 1/3 vests at one year, remainder over two years.
Annual retainer of $45,000 plus $5,000 for Nominating Committee service; eligible for annual option grants.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bernhardt Zeiher

Class I Director

AMLX · Amylyx Pharmaceuticals, Inc.

Effective: 2024-03-14
Filed: March 14, 2024, 7:59 PM ET

On March 14, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of Amylyx Pharmaceuticals, Inc. (the “Company”) appointed Bernhardt Zeiher, MD, FCCP, FACP to fill a vacancy on the Board as a Class I director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bernhardt Zeiher was appointed as Class I Director at Amylyx Pharmaceuticals, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

On March 14, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of Amylyx Pharmaceuticals, Inc. (the “Company”) appointed Bernhardt Zeiher, MD, FCCP, FACP to fill a vacancy on the Board as a Class I director

View on SEC.gov

Amylyx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-067471

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.